Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC deal

One of Shanda’s portfolio companies, the digital treatment developer Pear Therapeutics, is taking the SPAC track, going public through a deal expected to provide about $400 million in new funding as the company looks to expand its prescription apps to a wider range of conditions.


Those proceeds include $125 million gathered from private investments in Pear’s newfound public equity, plus $276 million held by Thimble Point Acquisition Corp., a blank-check company backed by the Pritzker Vlock Family Office, whose investment portfolio spans several medtech and biotech companies.


Read more


Photo credit: Getty Images

You might also interested in